COMT Genotype (Val158Met)

Two people in identical situations can respond to stress, pain, or a new medication in remarkably different ways. Part of that difference traces back to a single letter swap in a gene called COMT (catechol-O-methyltransferase), which produces an enzyme that clears dopamine and other signaling chemicals from your brain and body. Your version of this gene is set at birth and never changes.

This test reports which version you carry. The result is not a diagnosis and not a predictor of any one disease. It is a stable piece of background biology that can help explain patterns you may have noticed in yourself, and that may matter when you and a clinician are weighing certain medications or chronic pain questions.

What This Variant Actually Does

COMT Val158Met (also written as rs4680) is a single letter change in the COMT gene that swaps one building block of the enzyme for another. The result is one of three possible genotypes: Val/Val, Val/Met, or Met/Met. Each version produces an enzyme that works at a different speed.

The Met/Met version makes an enzyme with roughly three to four times lower activity than the Val/Val version, with Val/Met sitting in the middle. Slower enzyme activity means dopamine lingers longer, especially in the front part of the brain that handles planning, focus, and emotional regulation. Faster enzyme activity means dopamine is cleared more quickly. Neither pattern is universally better; they shift the balance in different directions.

This is a small but real biological effect. The enzyme also helps process estrogen and stress hormones, which is why the variant has been studied in pregnancy outcomes, pain conditions, and cardiovascular research, not only in cognition and psychiatry.

How Strong Is the Evidence

Before getting into specific health associations, it helps to know where this marker sits on the evidence spectrum. COMT Val158Met is a research and exploratory marker, not a guideline-recommended clinical screening test. Pooled analyses of thousands of people repeatedly find effects that are real but small in size, and many findings appear only in certain subgroups defined by sex, ancestry, or environment.

One large meta-analysis covering 363 datasets, 56,998 cases, and 74,668 controls described the relationship between COMT and psychiatric conditions as pleiotropic but generally small, which helps explain why single studies often disagree with each other. A separate meta-analysis of cognitive function found little to no broad cognitive advantage for any one genotype overall, despite earlier studies suggesting otherwise. Treat any single result here as one piece of context, not a verdict.

Cognition and the Prefrontal Brain

The most studied link is between COMT and the front part of the brain, where dopamine helps with working memory and executive function. A meta-analysis of the Wisconsin Card Sort Test, a standard executive-function task, found Met/Met healthy adults performed slightly better than Val/Val healthy adults, with an effect size of 0.29 (a small advantage). The same pattern did not hold in people with schizophrenia.

In a study of healthy adults genotyped from buccal cell samples, Met/Met carriers performed better across most of the cognitive domains tested, alongside the expected effect of younger age. The broader literature, though, suggests this is a trade-off rather than a pure win: higher dopamine tone may support stability and focus while slightly limiting cognitive flexibility.

Pain Sensitivity and Opioid Response

COMT has been studied repeatedly in chronic pain and opioid response, and this is one of the more practically interesting areas. People with the lower-activity Met/Met genotype tend to show greater pain sensitivity. In a brain imaging study using a sustained pain challenge, Met/Met participants had blunted natural pain-relief signaling and rated the same pain as more intense and more emotionally negative.

In cancer pain treatment, Val/Val patients needed about 155 mg of morphine per 24 hours, compared with 117 mg for Val/Met and 95 mg for Met/Met, a roughly 60% difference between the extremes. A separate cardiac surgery study found Met allele carriers reported more pain during a painful procedure even while on morphine. The direction of effect has not been uniform across all pain populations, though: some chronic pain and cancer pain studies have found Met carriers using greater opioid doses or experiencing more side effects rather than needing less medication. These findings do not change a standard pain plan on their own, but they help explain why some people need more or less of the same medication.

Fibromyalgia and Chronic Pain Conditions

Fibromyalgia evidence is mixed and depends on which question is being asked. A 2024 meta-analysis linked the Met allele to fibromyalgia risk overall and found Met/Met patients scored about 11 points higher on the Fibromyalgia Impact Questionnaire than Val/Val patients, suggesting worse symptom severity. A separate 2024 case-control study, in contrast, found Val/Val carriers had about twice the risk of fibromyalgia compared with Met/Met carriers, while Met/Met within cases was associated with more severe pain intensity.

These contradictions are not unusual for this marker. Both findings can be true in different populations, and they reflect the underlying truth: COMT shifts the dopamine setting, but the symptom that shows up depends heavily on context. In chronic tension-type headache, women with Met/Met had lower widespread pressure pain thresholds and higher depressive symptoms than Val/Val or Val/Met carriers.

Reconciling the Mixed Findings

It is tempting to read the opposing results above and conclude the test is useless. A more accurate reading is that this is not a good number or bad number marker; it is a setting, and which setting is helpful depends on the situation. Met/Met may favor focus and cognitive stability in calm conditions while increasing vulnerability to pain and emotional reactivity under stress. Val/Val may handle stress and high-demand conditions better while showing slower learning of certain new rules. The same gene, two different stories.

Medication Response in Psychiatry

One of the clearer signals in the literature is in how people with schizophrenia respond to antipsychotic medication. A 2016 meta-analysis pooling 15 samples found Met/Met patients were about 37% more likely to respond than Val carriers overall (odds ratio 1.37), with a larger effect for atypical antipsychotics, where Met/Met patients were about 54% more likely to respond (odds ratio 1.54). A later updated meta-analysis pooling 30 studies and more than 6,000 participants confirmed a significant overall relationship between COMT Val158Met and antipsychotic response across Caucasian and Asian populations.

In major depression, one study of 256 patients found Val/Val carriers had a worse response to antidepressants over four to six weeks compared with Val/Met carriers. The broader antidepressant literature is mixed and far from settled, so this does not mean any particular medication will or will not work for you. It is one piece of a pharmacogenetic picture that some clinicians use as one input among many.

Pregnancy and Cardiovascular Patterns

A meta-analysis of preeclampsia found COMT Val158Met was associated with about 52% higher risk of preeclampsia in the recessive model comparing Met/Met (AA) carriers with the other genotypes combined (odds ratio 1.522). A separate buccal-swab study, currently a preprint and not yet peer-reviewed, linked maternal Met/Met specifically to early-onset preeclampsia in both African American and Caucasian mothers, with no association seen for late-onset preeclampsia.

Coronary artery disease evidence is more population-specific. One Indian case-control study reported about 6 times higher odds of coronary artery disease for AA (Met/Met) versus GG (Val/Val) carriers (odds ratio 6.0). Other cardiovascular findings have been inconsistent, so this is best treated as a possible signal rather than an established risk pathway.

Breast Cancer and Parkinson's Disease

Two diseases where you might assume a strong COMT link actually show weak or null associations in the best available data. A breast cancer meta-analysis covering 34,358 patients and 45,429 controls found no significant association between COMT Val158Met and breast cancer risk in any genetic model tested. A pooled Parkinson's disease analysis found no overall association either, with signals appearing only in Japanese and Indian subgroups.

These null findings are useful. If you carry the higher-risk genotype for some conditions, it does not automatically mean elevated risk for every disease that involves dopamine or estrogen metabolism.

When Results Can Be Misleading

Because this is a genetic test, the usual concerns about timing, fasting, or recent illness do not apply. The confounders are different and worth understanding before drawing conclusions from a result.

• Variant panel coverage: this assay specifically detects the Val158Met (rs4680) site in the COMT gene. A negative or normal result does not rule out other rare COMT variants that the test does not look for.
• Ancestry-specific frequencies: the proportion of people carrying each genotype varies by population, and most large outcome studies have been done in Caucasian or East Asian groups. If you have a different ancestry, the published risk estimates may not transfer cleanly.
• Variant naming confusion: this variant is also called Val108/158Met, COMT G472A, or rs4680. If you have seen a related genetic report (including a 23andMe-style export), check the specific position before assuming the results match.
• Subgroup-specific effects: many published associations only appear in one sex, one ancestry, or one diagnosis. A statistically significant finding in a study group may not apply to you personally.

One-Time Result

You only need this test once in your lifetime. Your COMT genotype was set at conception and will be identical in any future sample. The value comes not from retesting but from integrating the result into ongoing decisions over years, particularly conversations with clinicians about pain management, psychiatric medications, or pregnancy planning.

If you decide to use this result clinically, the more useful ongoing testing is the relevant downstream phenotype rather than the genotype itself. That might mean tracking blood pressure carefully during pregnancy if Met/Met and considering early-onset preeclampsia risk, or revisiting pain control strategies with a clinician who knows your genotype. The genotype is the background; the phenotype is what you measure over time.

What to Do with an Unexpected Result

There is no universally abnormal COMT result. Each genotype has trade-offs, and the right next step depends entirely on what you came to the test for. A few practical pathways:

• If you have chronic pain or are facing surgery: share your genotype with your pain management or anesthesia team. The morphine dosing literature suggests Met/Met carriers may need less and Val/Val carriers may need more than average, though the direction has not been uniform across all pain settings. Major cancer pain guidelines currently describe the clinical importance of COMT in opioid response as unclear, so this informs rather than dictates dosing.
• If you are starting or switching psychiatric medication: a result is one piece of information among many. A psychiatrist familiar with pharmacogenetics can weigh it alongside your symptoms, side effect history, and other genetic markers.
• If you are pregnant or planning pregnancy with a Met/Met result: discuss closer blood pressure monitoring with your obstetric team, especially in the second trimester, given the early-onset preeclampsia signal, while noting that part of the supporting evidence is still a preprint.
• If your result is unexpected or you have a strong family history of a related condition: consider a one-time conversation with a genetic counselor. They can put this single SNP in the broader context of your family history and any other genetic testing you may have done.